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Introduction {#jdv16204-sec-0007}
============

Kaposi sarcoma (KS) has long remained the most common malignant condition in people living with HIV (PLWHIV). Although ART reduces the risk of KS and modifies its clinical features and prognosis,[1](#jdv16204-bib-0001){ref-type="ref"}, [2](#jdv16204-bib-0002){ref-type="ref"} KS continues to occur in ART‐treated patients, even in those with a sustained undetectable HIV‐plasma viral load (HIV‐pVL) and immune restoration.[3](#jdv16204-bib-0003){ref-type="ref"} To date, however, the prevalence of such clinical presentation has not been clearly identified.

We aimed to describe all KS cases observed between 2010 and 2015 in a large multicenter French cohort to determine who experienced KS in a country with high ART coverage.

Methods {#jdv16204-sec-0008}
=======

This multicenter retrospective analysis was performed using longitudinal data from the French Dat\'AIDS cohort (NCT 02898987 ClinicalTrials.gov). In 2010, this cohort represented a collaboration of 17 major French HIV clinical centres using a common electronic medical record for the follow‐up of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV)‐infected adults (NADIS^®^).[4](#jdv16204-bib-0004){ref-type="ref"} The data collection was approved by the French National Commission on Informatics and Liberty (CNIL 2001/762876; MR004 2210731v.0), and all patients signed an informed consent form before being included in this database. For this study, we selected patients followed in the cohort between 1 January 2010, and 31 December 2015, including those with a history of KS and/or malignant disease. ICD10 codes were used to identify KS cases (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD10), World Health Organization, Geneva), ICD code C46). The study period for patients included before to 1 January 2010, began on 1 January 2010; for patients included after 1 January 2010, the study period began at the date of cohort inclusion. The end of follow‐up was the date of KS occurrence.

First, KS cases were analysed according to ART exposure as follows: (i) ART‐naïve patients, (ii) patients who were ART experienced but not on ART at the time of KS diagnosis (iii) and patients on ART. Then, we selected patients on ART for more than 6 months and analysed their characteristics according to HIV‐pVL \>50 copies/mL or ≤50 copies/mL at the time of KS diagnosis. Gender, age, duration of HIV infection follow‐up, HIV transmission group, CDC stage, history of KS and/or malignant disease, hepatitis C (HCV) positive serology, nadir CD4 T‐cell count (cells/mm^3^; \<200, 200--500, \>500), CD4 and CD8 T‐cell count (cells/mm^3^; CD4: \<200, 200--500, \>500; CD8 \> 1000), CD4 : CD8 ratio (median, \<1 and ≥1), HIV‐pVL and time with HIV‐pVL ≤50 copies/mL, antiretroviral exposure (duration of ART exposure; ART regimen: nucleoside/tide reverse transcriptase inhibitor (NRTI)‐, non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐, boosted protease inhibitor (bPI)‐ or integrase strand transfer inhibitor (INSTI)‐based regimen and date of antiretroviral treatment initiation before: \<1995 (pre ART era), between 1996 and ‐2006 (ART era with PI availability), ≥2007 (ART era with INSTI availability) were collected at the time of KS diagnosis.

Statistical analyses were performed with SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata/SE software (version 14; StataCorp LP, College Station, TX, USA).

Results {#jdv16204-sec-0009}
=======

During the study period, 44 642 PLWHIV were included in the Dat\'AIDS cohort, of whom 13 543 were females (30.3%) and 31 099 were males (69.6%), representing 180 206 person‐years of follow‐up. Over the course of 180 2016 person‐years, 209 KS cases were diagnosed: 52 (24.9%) cases in 2010, 41 (19.6%) in 2011, 33 (15.8%) in 2012, 28 (13.4%) in 2013, 30 (14.4%) in 2014 and 25 (12%) in 2015.

Most cases occurred in males (91.9%) and men who have sex with men (MSM) (63.6%), with a median age of 43.0 years (IQR: 35.7; 49.9) and a median HIV time follow‐up of 2.1 years (IQR: 0.1; 9.4).

Description of 209 KS cases according to ART exposure at the time of KS diagnosis {#jdv16204-sec-0010}
---------------------------------------------------------------------------------

Among the 209 KS cases, ART status at time of KS diagnosis was not available in one patient; 69 KS cases occurred in ART‐naïve patients, of whom 41 patients had a concomitant HIV diagnosis with a median CD4 of 41/mm^3^ (IQR: 25;160); 36 KS cases occurred in patients who were ART experienced but not on ART at the time of KS diagnosis; and 103 KS cases occurred in patients on ART of whom 54 for more than 6 months (CD4/mm^3^): 252 \[53; 469\]). The patients' characteristics are reported in Table [1](#jdv16204-tbl-0001){ref-type="table"}. The distribution of KS cases according to these three conditions did not differ according to the year of diagnosis. Likewise, the median CD4 T‐cell count in ART‐naïve, ART‐experienced and ART‐treated patients at the time of KS diagnosis was similar each year of the study period (Fig. [1](#jdv16204-fig-0001){ref-type="fig"}).

###### 

Patient\'s characteristics of 209 KS cases according to ART exposure at time of KS diagnosis in the French Dat\'AIDS cohort between 2010 and 2015

  Median \[IQR\]; *N* (%)                           All                   ART Naive             ART interrupted       On ART                *P*
  ------------------------------------------------- --------------------- --------------------- --------------------- --------------------- ---------------------------------------------
  Gender                                                                                                                                    
  Male                                              192 (91.9)            64 (92.8)             34 (94.4)             93 (90.3)             0.84[a](#jdv16204-note-0006){ref-type="fn"}
  Female                                            17 (8.1)              5 (7.2)               2 (5.6)               10 (9.7)              
  Age (years)                                       43.0 \[35.7; 49.9\]   42.3 \[34.6; 49.2\]   43.7 \[35.2; 51.2\]   43.4 \[36.1; 49.3\]   0.10
  ≤25                                               4 (1.9)               2 (2.9)               0                     2 (1.9)               0.82[a](#jdv16204-note-0006){ref-type="fn"}
  25--50                                            153 (73.2)            52 (75.4)             25 (69.4)             76 (73.8)             
  \>50                                              52 (24.9)             15 (21.7)             11 (30.6)             25 (24.3)             
  \>65                                              7 (3.3)               4 (5.8)               0                     2 (1.9)               
  HIV Transmission group                                                                                                                    
  MSM                                               133 (63.6)            40 (58)               28 (77.8)             65 (63.1)             0.45[a](#jdv16204-note-0006){ref-type="fn"}
  Heterosexual                                      48 (23)               20 (29)               5 (13.9)              22 (21.4)             
  IVDU                                              6 (2.9)               1 (1.4)               1 (2.8)               4 (3.9)               
  Others/unknown                                    22 (10.6)             8 (11.6)              2 (5.6)               12 (11.7)             
  HIV time follow‐up (years)                        2.1 \[0.1; 9.4\]      0.1 \[0; 2.8\]        6 \[1.9; 13.7\]       5 \[0.3; 12.7\]       \<0.001
  ≤1                                                90 (43.1)             45 (65.2)             8 (22.2)              37 (35.9)             \<0.001
  \[1--5\]                                          33 (15.8)             12 (17.4)             6 (16.7)              15 (14.6)             
  \[5--10\]                                         37 (17.7)             7 (10.1)              9 (25)                21 (20.4)             
  \[10--15\]                                        24 (11.5)             2 (2.9)               7 (19.4)              15 (14.6)             
  15                                                25 (12.0)             3 (4.3)               6 (16.7)              15 (14.6)             
  Number of cases diagnosed/year                                                                                                            
  2010                                              52 (24.9)             16 (23.2)             7 (19.4)              29 (28.2)             0.51
  2011                                              41 (19.6)             16 (23.2)             5 (13.9)              20 (19.4)             
  2012                                              33 (15.8)             8 (11.6)              11 (30.6)             14 (13.6)             
  2013                                              28 (13.4)             11 (15.9)             3 (8.3)               14 (13.6)             
  2014                                              30 (14.4)             10 (14.5)             5 (13.9)              14 (13.6)             
  2015                                              25 (12.0)             8 (11.6)              5 (13.9)              12 (11.7)             
  Stage C at KS (*n* = 206)                                                                                                                 
  Yes                                               58 (27.8)             8 (11.8)              8 (22.2)              41 (40.6)             \<0.001
  No                                                148 (70.8)            60 (88.2)             28 (77.8)             60 (59.4)             
  HCV coinfection                                                                                                                           
  No                                                191 (91.4)            63 (91.3)             33 (91.7)             94 (91.3)             1[a](#jdv16204-note-0006){ref-type="fn"}
  Yes                                               18 (8.6)              6 (8.7)               3 (8.3)               9 (8.7)               
  Nadir CD4 cell count/mm^3^                        123 \[30; 264\]       105 \[35; 311\]       150 \[53; 296\]       122 \[15; 250\]       0.34
  \<200/mm^3^                                       121 (57.9)            36 (66.7)             22 (61.1)             62 (60.8)             0.32[a](#jdv16204-note-0006){ref-type="fn"}
  200--500/mm^3^                                    62 (29.7)             15 (27.8)             10 (27.8)             37 (36.3)             
  \>500/mm^3^                                       10 (4.8)              3 (5.6)               4 (11.1)              3 (2.9)               
  CD4 T‐cell count/mm^3^                            188 \[49; 360\]       90 \[33; 267\]        184 \[93; 428\]       243 \[61; 429\]       0.12
  \<200/mm^3^                                       107 (51.2)            45 (69.2)             18 (52.9)             44 (42.7)             0.02[a](#jdv16204-note-0006){ref-type="fn"}
  200‐500/mm^3^                                     69 (33)               14 (21.5)             10 (29.4)             44 (42.7)             
  \>500/mm^3^                                       27 (12.9)             6 (9.2)               6 (17.6)              15 (14.6)             
  CD8 T‐cell count/mm^3^                            761 \[463; 1247\]     659 \[383; 1154\]     863 \[647; 1057\]     798 \[512; 1296\]     0.25
  \>1000/mm^3^                                      62 (29.7)             18 (29.5)             9 (28.1)              35 (38.9)             0.37
  CD4 : CD8 ratio                                   0.2 \[0.1; 0.4\]      0.11 \[0.04; 0.29\]   0.18 \[0.05; 0.38\]   0.22 \[0.05; 0.42\]   0.10
  \<1                                               175 (83.7)            60 (98.4)             31 (100)              83 (92.2)             0.12[a](#jdv16204-note-0006){ref-type="fn"}
  ≥1                                                8 (3.8)               1 (1.6)               0                     7 (7.8)               
  HIV‐pVL (Log/mL)                                  4.6 \[2.2‐5.4\]       5.2 \[4.8; 5.7\]      5 \[4; 5.6\]          2.6 \[1.6; 4.6\]      \<0.001
  HIV‐pVL copies/mL (205)                                                                                                                   
  ≤50                                               38 (18.5)             1 (1.5)               4 (11.4)              32 (31.4)             \<0.001
  51--1000                                          33 (16.1)             4 (6)                 3 (8.6)               26 (25.5)             
  1001--10 000                                      16 (7.8)              1 (1.5)               2 (5.7)               13 (12.7)             
  10 001--100 000                                   36 (17.6)             18 (26.9)             9 (25.7)              9 (8.8)               
  \>100 001                                         82 (40.0)             43 (64.2)             17 (48.6)             22 (21.6)             
  Time with HIV‐pVL ≤ 50 (years)                    0.4 \[0.1; 2.6\]      --                    2.4 \[0.9; 3.7\]      0.4 \[0.1; 2.6\]      0.16
  On first line of ART                              51 (24.4)             --                    --                    51 (49.5)             
  Time exposure to ART (years)                      0.7 \[0.2; 6.8\]      --                    --                    0.7 \[0.2; 6.6\]      
  ART initiation                                                          --                    --                                          
  Before 1995                                       4 (3.9)               NA                    NA                                          
  1996--2006                                        23 (22.3)             NA                    NA                                          
  ≥2007                                             76 (73.8)             NA                    NA                                          
  Time exposure to the last ART (m)                 2.7 \[0.7; 10.4\]     NA                    NA                    2.7 \[0.7; 10.4\]     
  Last ART regimen                                                        --                    --                                          
  2NRTI + 1bPI                                      60 (28.7)             NA                    NA                    60 (58.3)             
  2NRTI + 1NNRTI                                    13 (6.2)              NA                    NA                    13 (12.6)             
  2NRTI + 1INSTI                                    9 (4.3)               NA                    NA                    9 (8.7)               
  Others[c](#jdv16204-note-0005){ref-type="fn"}NA   21 (10)               NA                    NA                    21 (20.4)             
  Previous malignant disease                        10 (4.8)              5 (7.2)               1 (2.8)               3 (2.9)               0.40[a](#jdv16204-note-0006){ref-type="fn"}
  Kaposi localization                                                                                                                       
  Cutaneous                                         140 (67.0)            47 (68.1)             21 (58.3)             72 (69.9)             0.93
  Oral mucosa/palate                                15 (7.2)              4 (5.8)               4 (11.1)              7 (6.8)               
  Bronchopulmonary                                  11 (5.3)              4 (5.8)               1 (2.8)               6 (5.8)               
  Intestinal                                        9 (4.3)               3 (4.3)               3 (8.3)               3 (2.9)               
  Lymph node                                        7 (3.3)               2 (2.9)               1 (2.8)               3 (2.9)               
  Disseminated                                      6 (2.9)               3 (4.3)               1 (2.8)               2 (1.9)               
  Data not available                                21 (10.0)             6 (8.7)               5 (13.9)              10 (9.7)              

NA, not applicable.

Fisher exact test.

ART status was not available in one patient.

Others: 2NRTI + CCR5‐inhibitor: *n* = 1; bPI + INSTI: *n* = 2; bPI + CCR5‐inhibitor: *n* = 2; 1NRTI + 1bPI: *n* = 2; 1NRTI + 1bPI + 1INSTI: *n* = 1; 1NRTI + 1NNRTI + 1bPI: *n* = 1; 1NNRTI + 1bPI + CCR5‐inhibitor: *n* = 1; 2NRTI + 1bPI + 1INSTI: *n* = 3; 2NRTI + 1bPI + CCR5‐inhibitor: *n* = 2; 2NRTI + 1NNRTI + 1bPI + T20: *n* = 1; 2NRTI + 1NNRTI + 1bPI + INSTI: *n* = 2; 2NRTI + INSTI:1; 2NRTI + 2NNRTI:1; 3NRTI + bPI: *n* = 1.

John Wiley & Sons, Ltd

![Median CD4 T‐cell count in 209 patients with Kaposi sarcoma according to ART exposure at time of KS diagnosis in the French DAT'AIDS cohort between 2010 and 2015.](JDV-34-1065-g001){#jdv16204-fig-0001}

The three groups did not differ in median age, sex ratio or HIV transmission groups, but the median duration of HIV follow‐up was significantly lower in ART‐naïve patients, most of whom were followed since 1 year or less.

The proportion of prior CDC stage C at the time of KS diagnosis was significantly higher in patients on ART (*P* \< 0.001). The nadir CD4 and median CD4 T‐cell count as the CD4 : CD8 ratio did not differ between the three groups, but the proportion of patients with CD4 ≤200/mm^3^ at the time of KS diagnosis was significantly lower in patients on ART than in the other two groups.

HIV‐pVL was significantly higher among ART‐naïve patients. Although the number of patients with HIV‐pVL ≤50 copies/mL was significantly higher in patients on ART (*n* = 32 (31.4%), one ART‐naïve patient and four experienced ART patients had HIV‐pVL ≤50 copies/mL.

Data concerning KS localization were available for 188 patients (89.9%). Overall, the most frequent KS localization was cutaneous in 67% of cases, followed by oromucosal in 7.2%, bronchopulmonary in 5.3%, intestinal in 4.3% and nodal in 3.3%. In 2.9% of cases, KS was disseminated. The distribution of KS localization did not differ between the three groups or by year of diagnosis (Table [2](#jdv16204-tbl-0002){ref-type="table"}). However, patients aged more than 50 years had more visceral (i.e. bronchopulmonary, intestinal, lymph nodes) and disseminated localization (*P*=0.04) than those aged \<50 (Table [3](#jdv16204-tbl-0003){ref-type="table"}).

###### 

Kaposi localization distribution by year of diagnosis of 209 KS cases diagnosed between 2010 and 2015 in the French Dat\'AIDS Cohort

  Kaposi localization   2010        2011        2012        2013        2014        2015      *P*
  --------------------- ----------- ----------- ----------- ----------- ----------- --------- ------
  Skin                  40 (76.9)   30 (73.2)   20 (60.6)   20 (71.4)   19 (63.3)   11 (44)   0.41
  Oral mucosa/palate    1 (1.9)     3 (7.3)     3 (9.1)     3 (10.7)    1 (3.3)     4 (16)    
  Bronchopulmonary      3 (5.8)     1 (2.4)     2 (6.1)     1 (3.6)     2 (6.7)     2 (8)     
  Intestinal            1 (1.9)     0           2 (6.1)     2 (7.1)     1 (3.3)     3 (12)    
  Lymph node            1 (1.9)     2 (4.9)     0           1 (3.6)     2 (6.7)     1 (4)     
  Disseminated          2 (3.8)     3 (7.3)     1 (3)       0           0           0         
  Data not available    4 (7.7)     2 (4.9)     5 (15.2)    1 (3.6)     5 (16.7)    4 (16)    

John Wiley & Sons, Ltd

###### 

Kaposi localization distribution according to age ≥ or \<50 years of 209 KS cases diagnosed between 2010 and 2015 in the French Dat\'AIDS Cohort

  Kaposi localization[a](#jdv16204-note-0007){ref-type="fn"}   Age \< 50 years   Age ≥ 50 years   *P*
  ------------------------------------------------------------ ----------------- ---------------- ------
  Skin                                                         103 (74.6)        37 (74)          0.04
  Oral mucosa/palate                                           14 (10.1)         1 (2.0)          
  Visceral                                                     18 (13.0)         9 (18.0)         
  Bronchopulmonary                                             6 (33.0)          5 (55.5)         
  Intestinal                                                   8 (44.4)          1 (11.1)         
  Lymph node                                                   4 (22.2)          3 (33.3)         
  Disseminated                                                 3 (1.9)           3 (6.0)          

Data not available for 19 (12.1) of patients aged \<50 and for 2 (3.8) of patients aged ≥50.

John Wiley & Sons, Ltd

Description of 54 KS cases in patients on ART for more than 6 months {#jdv16204-sec-0011}
--------------------------------------------------------------------

Among the 103 patients on ART, 54 patients were on ART for more than 6 months, of whom 24 patients had HIV‐pVL ≤50 copies/mL, with a median time of 0.58 years \[IQR: 0.26; 3\], and 30 patients had HIV‐pVL \>50 copies/mL \[median HIV‐pVL: 3.4 (IQR: 2.3--4.9)\] at the time of KS diagnosis. The patients' characteristics are reported in Table [4](#jdv16204-tbl-0004){ref-type="table"}.

###### 

Patient\'s characteristics at time of KS diagnosis of KS cases occurred in patients on ART for more than 6 months between 2010 and 2015 in the French Dat\'AIDS cohort according to HIV‐pVL \> or ≤50 copies/mL

  Median \[IQR\] or *N* (%)                                KS on ART[†](#jdv16204-note-0004){ref-type="fn"} with HIV VL \> 50 cp/mL *n* = 30   KS on ART[†](#jdv16204-note-0004){ref-type="fn"} with HIV VL ≤ 50 cp/mL *n* = 24   *P*
  -------------------------------------------------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------
  Age (years)                                              43.5 \[36; 51.2\]                                                                   48.2 \[39; 54.7\]                                                                  0.14
  Gender                                                                                                                                                                                                                          
  Male                                                     26 (86.7)                                                                           21 (87.5)                                                                          1
  Female                                                   4 (13.3)                                                                            3 (12.5)                                                                           
  HIV Transmission group                                                                                                                                                                                                          
  MSM                                                      16 (53.3)                                                                           14 (58.3)                                                                          0.46
  Heterosexual                                             7 (23.3)                                                                            8 (33.3)                                                                           
  IVDU                                                     2 (6.7)                                                                             1 (4.2)                                                                            
  Others/unknown                                           5 (16.7)                                                                            1 (4.2)                                                                            
  HIV time follow‐up (y)                                   12.8 \[6.4; 15.8\]                                                                  7.4 \[2.8; 20.7\]                                                                  0.21
  ≤1                                                       0                                                                                   3 (12.5)                                                                           0.14
  \[1--5\]                                                 2 (6.7)                                                                             5 (20.8)                                                                           
  \[5--10\]                                                11 (36.7)                                                                           6 (25)                                                                             
  \[10--15\]                                               9 (30)                                                                              4 (16.7)                                                                           
  15                                                       8 (26.7)                                                                            6 (25)                                                                             
  Year of diagnosis                                                                                                                                                                                                               
  2010                                                     10 (33.3)                                                                           1 (4.2)                                                                            
  2011                                                     5 (16.7)                                                                            5 (20.8)                                                                           0.05[a](#jdv16204-note-0009){ref-type="fn"}
  2012                                                     5 (16.7)                                                                            5 (20.8)                                                                           
  2013                                                     1 (3.3)                                                                             5 (20.8)                                                                           
  2014                                                     6 (20)                                                                              3 (12.5)                                                                           
  2015                                                     3 (10)                                                                              5 (20.8)                                                                           
  Stage C at KS                                                                                                                                                                                                                   
  Yes                                                      12 (42.9)                                                                           7 (29.2)                                                                           0.31
  No                                                       16 (57.1)                                                                           17 (70.8)                                                                          
  Nadir CD4/mm^3^                                          13 \[5; 154\]                                                                       242 \[120; 363\]                                                                   \<0.001
  \<200/mm^3^                                              22 (75.9)                                                                           9 (37.5)                                                                           0.005
  CD4/mm^3^                                                69 \[12; 301\]                                                                      467 \[255; 819\]                                                                   \<0.001
  CD4 \< 200/mm^3^                                         19 (63.3)                                                                           4 (16.7)                                                                           0.001
  CD4 \> 500/mm^3^                                         1 (3.3)                                                                             9 (37.5)                                                                           0.003[a](#jdv16204-note-0009){ref-type="fn"}
  CD8/mm^3^                                                665 \[507; 1321\]                                                                   960 \[662; 1360\]                                                                  0.30
  CD8 ≥ 1000/mm^3^                                         9 (37.5)                                                                            10 (41.7)                                                                          0.77
  Ratio CD4 : CD8                                          0.2 \[0; 0.3\]                                                                      0.5 \[0.2; 0.9\]                                                                   \<0.001
  Ratio \< 1                                               24 (100)                                                                            18 (75)                                                                            0.022[a](#jdv16204-note-0009){ref-type="fn"}
  HIV‐pVL (log/mL)                                         3.4 \[2.3; 4.9\]                                                                    NA                                                                                 
  ART‐Time exposure (years)                                8 \[3.9; 13.1\]                                                                     4.1 \[1; 10.3\]                                                                    0.16
  ART initiation                                                                                                                                                                                                                  
  Before 1995                                              2 (6.7)                                                                             2 (8.3)                                                                            0.30[a](#jdv16204-note-0009){ref-type="fn"}
  1996--2006                                               15 (50)                                                                             7 (29.2)                                                                           
  ≥2007                                                    13 (43.3)                                                                           15 (62.5)                                                                          
  Time exposure to the last ART (m)                        3.9 \[0.9; 12.4\]                                                                   13.8 \[7.6; 28.9\]                                                                 0.001
  Last ART                                                                                                                                                                                                                        
  2NRTI + 1bPI                                             17 (56.7)                                                                           8 (33.3)                                                                           0.25[a](#jdv16204-note-0009){ref-type="fn"}
  2NRTI + 1NNRTI                                           2 (6.7)                                                                             5 (20.8)                                                                           
  2NRTI + 1INSTI                                           3 (10)                                                                              2 (8.3)                                                                            
  Others[&ddagger;](#jdv16204-note-0005){ref-type="fn"}    8 (26.7)                                                                            9 (37.5)                                                                           
  KS Localization[b](#jdv16204-note-0012){ref-type="fn"}                                                                                                                                                                          
  Cutaneous                                                20 (66.7)                                                                           18 (75.0)                                                                          0.57
  Oral mucosa/palate                                       1 (3.3)                                                                             2 (8.3)                                                                            
  Bronchopulmonary                                         4 (13.3)                                                                            1 (4.2)                                                                            
  Intestinal                                               0                                                                                   0                                                                                  
  Lymph node                                               2 (6.7)                                                                             0                                                                                  
  Disseminated                                             0                                                                                   0                                                                                  

b, boosted; INSTI, integrase strand transfer inhibitor; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitor; NRTI, nucleotide reverse transcriptase inhibitor; PI, boosted protease inhibitor.

Fisher exact test.

For more than 6 months.

Others: 2NRTI + CCR5‐inhibitor: *n* = 1; bPI + INSTI: *n* = 2; bPI + CCR5‐inhibitor: *n* = 1; 1NRTI + 1bPI: *n* = 1; 2NRTI + 1bPI + 1INSTI: *n* = 2; 2NRTI + 1bPI + CCR5‐inhibitor: *n* = 1; 3NRTI + bPI: *n* = 1.

Data not available for 3 (10.0) patients with HIV‐pVL \>50 cp/mL and for 3 (12.5) patients with HIV VL ≤50 cp/mL.

John Wiley & Sons, Ltd

The two groups did not differ in median age, sex ratio and HIV transmission groups or time of HIV follow‐up. The distribution of KS cases that occurred in patients on ART according to HIV‐pVL differed by the year of diagnosis. Indeed, 33% of KS cases in patients with detectable HIV‐pVL occurred in 2010, while in patients with undetectable HIV‐pVL, most KS cases occurred after 2010. Data concerning KS localization were available for 48 patients (88.8%), and the distribution of KS localization did not differ between the two groups. Patients on ART with HIV‐pVL ≤50 copies/mL presented significantly better immune parameters (median CD4 count and %, %CD4 \>500/mm^3^, nadir CD4, ratio CD4 : CD8) than those with detectable HIV‐pVL. Moreover, the proportion of patients with nadir \<200/mm^3^ was significantly higher in patients with detectable HIV‐pVL, as was the proportion of patients with CD4 : CD8 ratio \<1, but the two groups did not differ in CD8 T‐cell count (median and proportion with CD8 ≥1000/mm^3^).

Antiretroviral therapy‐time exposure and period of ART initiation were similar regardless of the detectability of HIV‐pVL, but time exposure to the last treatment was significantly higher in patients with undetectable HIV‐pVL. Additionally, the last ART regimen did not differ between those two groups. Among the 24 patients on ART with HIV‐pVL ≤50 copies/mL, sixteen patients (66%) were treated with an ART regimen including a bPI (darunavir/ritonavir in 12 patients, atazanavir/ritonavir in 3 and lopinavir/ritonavir in 1). There were five patients (21%) receiving an ART regimen including one NNRTI (efavirenz: *n* = 4; nevirapine: *n* = 1), six patients (25%), one INSTI (raltegravir) and three patients, a CCR5‐inhibitor (maraviroc). Nine patients were on their first line of ART, including five patients treated with 2NRTI + 1bPI, two patients treated with 2NRTI + 1NNRTI, one patient treated with 2NRTI + 1bPI + CCR5‐inhibitor and one patient treated with 2NRTI + 1 CCR5‐inhibitor. For these patients, the median delay of KS occurrence was 13.8 months (IQR: 10.7; 21.3). Six patients were on a second line of ART with a median delay of KS occurrence after the switch of 6.6 months (IQR: 5;7.5). Among them, 3 were treated with a bPI‐based regimen, one with an NNRTI‐based regimen and one with an INSTI‐based regimen. Eight patients were previously exposed to 3 or more lines of ART (3 to \>10).

Discussion {#jdv16204-sec-0012}
==========

In this retrospective study performed on a large cohort of PLWHIV, the prevalence of KS cases was 0.47%. This low prevalence rate is in line with the trend of KS incidence, which has declined since 1996 in France and in other resource‐rich countries, as we recently reported.[5](#jdv16204-bib-0005){ref-type="ref"}

However, more relevantly, this analysis highlights the need to differentiate KS occurrence circumstances in the post‐ART period, half of them occurring in patients not on ART, of whom 41 had concomitant HIV diagnosis. These patients fulfilled the criteria defining late presenters among HIV‐infected people, a situation that has remained common around the world,[6](#jdv16204-bib-0006){ref-type="ref"}, [7](#jdv16204-bib-0007){ref-type="ref"} including in France as we reported recently,[8](#jdv16204-bib-0008){ref-type="ref"} and which increases patient morbidity and mortality and limits the effectiveness of all subsequent steps in the cascade of HIV care.[9](#jdv16204-bib-0009){ref-type="ref"}, [10](#jdv16204-bib-0010){ref-type="ref"}

In our study, KS cases that occurred in late presenters were observed indifferently throughout the study period. This persistent delay in HIV testing in France stresses the need to reinforce HIV screening strategies in our country. Although KS may have different clinical presentations[11](#jdv16204-bib-0011){ref-type="ref"} (sometimes atypical[12](#jdv16204-bib-0012){ref-type="ref"}) and should occur in conditions other than HIV infection,[13](#jdv16204-bib-0013){ref-type="ref"}, [14](#jdv16204-bib-0014){ref-type="ref"} nevertheless, cutaneous and mucosal involvement are the most frequent,[15](#jdv16204-bib-0015){ref-type="ref"} as we have reported herein, highlighting the important role of dermatologists and general practitioners in HIV screening. Two recent studies reported, however, that much progress remains to be made in this area.[16](#jdv16204-bib-0016){ref-type="ref"}, [17](#jdv16204-bib-0017){ref-type="ref"}

The 36 KS cases occurring in patients who stopped ART confirms the importance of improving retention in care with a specific strategy, as recently reported.[18](#jdv16204-bib-0018){ref-type="ref"}

This study also highlights that not being on ART or being on ART with a persistence of HIV replication remains a risk factor for KS;[19](#jdv16204-bib-0019){ref-type="ref"} apart from worsening immune deficiency, the lack of control of HIV viral replication allows the promoting effect of HIV‐1 Tat protein on HHV8‐induced angiogenesis and tumorigenesis.[20](#jdv16204-bib-0020){ref-type="ref"}, [21](#jdv16204-bib-0021){ref-type="ref"}

However, more worryingly, this study highlights, as observed in studies performed over previous calendar periods,[3](#jdv16204-bib-0003){ref-type="ref"}, [22](#jdv16204-bib-0022){ref-type="ref"}, [23](#jdv16204-bib-0023){ref-type="ref"} that a sustained undetectable HIV viral load and a high CD4 cell count on ART is not enough to completely prevent KS occurrence. In our cohort, 11.4% of KS cases occurred in patients on ART for more than 6 months with an undetectable HIV‐pVL. This rate is higher than that reported in a recent retrospective study conducted between 1987 and 2011 in a German cohort of 16 500 HIV‐infected patients in which 7.4% of KS cases had HIV‐pVL ≤50 copies/mL.[3](#jdv16204-bib-0003){ref-type="ref"} Some clinicians wondered about the possible impact of new ART guidelines,[24](#jdv16204-bib-0024){ref-type="ref"}, [25](#jdv16204-bib-0025){ref-type="ref"} which recommend an INSTI‐based regimen as the first line and advocate optimizing ART with less risk of drug‐drug interactions between antiretroviral drugs and concomitant medications, especially for older patients.[26](#jdv16204-bib-0026){ref-type="ref"}, [27](#jdv16204-bib-0027){ref-type="ref"} In our study, most patients with undetectable HIV‐pVL were treated with a bPI‐based regimen at the time of KS diagnosis, including those in first line of ART, and when we considered KS cases that occurred after ART switching, most of them switched for a bPI‐based regimen. This result is not consistent with that of a previous study showing that a lower KS incidence was associated with bPI exposure for at least 3 years.[28](#jdv16204-bib-0028){ref-type="ref"} However, in our cohort, the median time of exposure to the last treatment in patients with undetectable HIV‐pVL was shorter than 3 years. The objective of this study was not to investigate factors associated with KS in patients on ART with undetectable HIV‐pVL, such as premature immune senescence or the loss of specific HHV8 immunity.[29](#jdv16204-bib-0029){ref-type="ref"}, [30](#jdv16204-bib-0030){ref-type="ref"} However, regardless of the cause, such KS cases, although few, remained steady throughout the study period, stressing the need to maintain a cautious examination and follow‐up of PLWHIV.

In this cohort, the distribution of KS localization did not differ according to the year of diagnosis, but patients aged over 50 had a higher percentage of visceral/disseminated forms. Specific clinical features in paediatric KS with more extensive and severe forms and a predilection for primary lymph node involvement are well identified.[31](#jdv16204-bib-0031){ref-type="ref"} We did not find any previous report on specific features of KS according to age in adult HIV‐infected people. Thus, our results should be confirmed by further studies.

This study has several limitations. First, virological data on human herpesvirus 8 (HHV8)[32](#jdv16204-bib-0032){ref-type="ref"} were not available. Thus, we could not determine whether KS cases in patients on ART with undetectable HIV‐pVL were related to HHV8 reactivation or even to HHV8 primary infection. In our study, 58% of affected individuals were men who have sex with men (MSM). High‐risk sexual behaviours with unprotected sex and concomitant sexually transmitted diseases are two factors associated with HHV8 infection in MSM.[33](#jdv16204-bib-0033){ref-type="ref"} Unfortunately, sexual behaviour data, condom use and previous or concomitant sexually transmitted disease at the time of KS diagnosis were not collected. Second, the study design did not allow us to clearly identify KS cases related to an immune reconstitution syndrome, as CD4 T‐cell count data were not collected at the time of first ART initiation. Third, we could not determine the median delay of KS occurrence in experienced ART patients, as no information concerning the time of treatment withdrawal was available. Fourth, among patients on ART with undetectable HIV‐pVL who switched ART, the reasons for switching were not reported, nor was the previous ART regimen before the switch. Finally, treatment modalities for KS and response rate data were not collected, which did not allow us to evaluate the percentage of patients requiring new therapeutic options.[34](#jdv16204-bib-0034){ref-type="ref"}

Conclusion {#jdv16204-sec-0013}
==========

Although the KS prevalence among PLWHIV remained low between 2010 and 2015 in France, this retrospective study highlights the persistent delay in HIV testing in France and the need to reinforce HIV screening strategies in our country. KS occurrence in patients who have discontinued ART confirms the importance of improving retention in care, and KS cases in patients on ART with control of viremia reinforces the need to maintain cautious examination and follow‐up, including for patients on a bPI‐based regimen. Further studies are needed to better understand KS pathogenesis mechanisms.
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